- Home
- RDVT vs AUTL Comparison
RDVT vs AUTL Comparison
Compare RDVT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- AUTL
- Stock Information
- Founded
- RDVT 2017
- AUTL 2014
- Country
- RDVT United States
- AUTL United Kingdom
- Employees
- RDVT N/A
- AUTL N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDVT Technology
- AUTL Health Care
- Exchange
- RDVT Nasdaq
- AUTL Nasdaq
- Market Cap
- RDVT 538.6M
- AUTL 590.8M
- IPO Year
- RDVT N/A
- AUTL 2018
- Fundamental
- Price
- RDVT $36.75
- AUTL $1.59
- Analyst Decision
- RDVT Strong Buy
- AUTL Strong Buy
- Analyst Count
- RDVT 1
- AUTL 4
- Target Price
- RDVT $25.00
- AUTL $9.15
- AVG Volume (30 Days)
- RDVT 78.7K
- AUTL 1.3M
- Earning Date
- RDVT 05-07-2025
- AUTL 03-20-2025
- Dividend Yield
- RDVT 0.80%
- AUTL N/A
- EPS Growth
- RDVT N/A
- AUTL N/A
- EPS
- RDVT 0.50
- AUTL N/A
- Revenue
- RDVT $75,189,000.00
- AUTL $10,120,000.00
- Revenue This Year
- RDVT $15.93
- AUTL $274.71
- Revenue Next Year
- RDVT $13.85
- AUTL $239.55
- P/E Ratio
- RDVT $74.66
- AUTL N/A
- Revenue Growth
- RDVT 24.89
- AUTL 496.00
- 52 Week Low
- RDVT $16.56
- AUTL $1.56
- 52 Week High
- RDVT $43.44
- AUTL $6.31
- Technical
- Relative Strength Index (RSI)
- RDVT 41.59
- AUTL 34.58
- Support Level
- RDVT $37.89
- AUTL $1.58
- Resistance Level
- RDVT $40.88
- AUTL $1.70
- Average True Range (ATR)
- RDVT 1.32
- AUTL 0.12
- MACD
- RDVT -0.13
- AUTL -0.01
- Stochastic Oscillator
- RDVT 12.99
- AUTL 3.30
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.